Abstract Background: Platelet aggregation occurs as a central role in acute coronary syndrome (ACS), and glycoprotein GP IIb/IIIa inhibitors may enhance the benefits expected from early recanalisation. Aim: To compare the degree of platelet aggregation inhibition achieved by Eptifibatide versus high dose Tirofiban, and its clinical effects regarding myocardial reperfusion parameters: myocardial blush grade (MBG) and ST-segment resolution (STR) >70%, and regarding peri procedural complications, bleeding and major adverse cardiac events (MACE). Methods: Between the period of June 2010-January 2012, 46 patients with acute myocardial infarction whose symptom onset is within 12 h of presentation and ECG showing ST-segment elevation 1 mm in two contiguous limb leads or 2 mm in two contiguous precordial leads or acute left bundle branch block were included. Exclusion criteria were active bleeding, thrombocytopenia, bleeding diathesis, anticoagulation or thrombolitics, recent major surgery or stroke, cardiogenic shock, and pregnancy. Patients were randomized alternatively (1:1) into two groups before primary percutaneous cardiac intervention (PCI) to receive the specific glycoprotin IIb/IIIa inhibitor as follows: (I) Tirofiban group: intravenous high bolus dose of 25 mcg/kg over 3 min followed by maintenance infusion of 0.15 mcg/kg/min. (II) Eptifibatide group: intravenous two boluses 10 min apart (each one is 180 mcg/kg) followed by maintenance of 2 mcg/kg/min. Platelet aggregation inhibition was measured by light transmission aggregometer, angiographic assessment was done before and after final interventions for TIMI flow and myocardial blush grade before and after the procedure. Electrocardiographic assessment standard 12-lead ECG on admission, immediately after PCI. Resolution of ST segment elevation was expressed as a percentage of the initial ST segment elevation. Resolution of P70% was defined as complete resolution. • Platelet aggregation inhibition during PCI was significantly correlated with STR and MBG. Platelet aggregation inhibition cut-off point as a predictor of STR >70% was 89.5%, and as a predictor of MBG 2-3 was 87.5%.
Clinical safety assessment was done in terms of the incidence of: bleeding complications and major adverse cardiac events (MACE): death, non-fatal myocardial infarction (MI), and target vessel revascularization (TVR). Results: The total patients in our study included 46 patients, 40 males (87%) and six females (13%) with a mean age of 55 ± 10, Tirofiban group: included 23 patients, 19 males (82.5%) and four females (17.4%) with a mean age of 57 ± 9.65. Eptifibatide group: included 23 patients, 21 males (87%) and two females (8.7%) with a mean age of 53.48 ± 8.6. Platelet aggregation inhibition during PCI was significantly correlated with STR (p 0.013, r 0.71). The cut-off point for platelet aggregation inhibition as a predictor of STR >70% was 89.5% (sensitivity 92.3%, specificity 69.2%, PPV 75% and NPV 10%, AUC 0.87). Platelet aggregation inhibition during PCI was positively correlated with MBG (p 0.045, r 0.453). The cut-off point for platelet aggregation inhibition as a predictor of MBG 2-3 was 87.5% (sensitivity 73.6%, specificity 66.7%, PPV 93.9% and NPV 76.9%, AUC 0.81). Platelet aggregation inhibition 60 min after bolus was (93.57 ± 2.07% versus 87.62 ± 3.2%, p < 0.001) and 6 h later (89.85 ± 2.03% versus 78.5 ± 7.07%, p < 0.001) in Eptifibatide versus Tirofiban groups, respectively. Post procedural TIMI flow III was (95.7% versus 91.3%, p 1), mean MBG (2.87 ± 0.34 versus 2.09 ± 0.73, p < 0.001) and STR >70% (56.22% versus 39.13%, p 0.005) in Eptifibatide versus Tirofiban group, respectively. There was no significant statistical difference regarding thrombocytopenia (46.73 ± 41.48 versus 39.04 ± 34.41, p 0.37), minor bleeding (17.4% versus 21.7%, p 0.5), major bleeding (0% versus 4.3%, p 0.5), post procedural infarction (0% versus 17.4%, p 0.12), TVR (0% versus 8.7%, p 0.24), MACE and 30 days mortality (4.3% versus 13%, p 0.34) in Eptifibatide versus Tirofiban group, respectively. Conclusions:
• Platelet aggregation inhibition during PCI was significantly correlated with STR and MBG. Platelet aggregation inhibition cut-off point as a predictor of STR >70% was 89.5%, and as a predictor of MBG 2-3 was 87.5%.
• Eptifibatide achieves better platelet aggregation inhibition 60 min after bolus and 6 h after PCI than high dose Tirofiban.
• Eptifibatide is associated with better myocardial perfusion as indicated by post procedural mean MBG and STR >70% than high dose Tirofiban.
• There was no significant differences between Eptifibatide and high dose Tirofiban regarding thrombocytopenia, major or minor bleeding, MACE and 30 days mortality.
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Introduction
Platelet aggregation occurs as a central role of an interconnected pattern of plaque disruption, lipid accumulation, mural thrombus formation, and lesion progression in acute coronary syndrome (ACS). When plaque rupture occurs, the subendothelial protein matrix is disrupted, allowing platelet adhesion molecules such as Von Willebrand factor and collagen to interact with circulating platelets with platelet activation and degranulation. 1 Early administration of glycoprotein GP IIb/ IIIa inhibitors is more valuable for the potential benefits expected from early recanalisation 2,3 abciximab has been shown to reduce mortality in patients undergoing primary angioplasty. 4, 5 Abciximab is recommended as class IIa (level of evidence A), Eptifibatide as class IIa (level of evidence B) while Tirofiban class IIb (level of evidence B) according to the current guidelines of the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS 2010). 6 There has not been to date, to our knowledge, any large randomized studies directly comparing Eptifibatide versus high dose Tirofiban as regards platelet aggregation inhibition and myocardial reperfusion parameters in patients with ST segment myocardial infarction (STEMI). One study (Jianjin Tang et al., 2008) compared both drugs regarding efficacy and safety in non-ST segment elevation ACS (UA/NSTEMI) and concluded that Eptifibatide decreases ischemic events without significant differences in bleeding complications. Tirofiban regarding peri procedural complications, bleeding and major adverse cardiac events (MACE).
Aim of the work

Patients and methods
Between the period of June 2010-January 2012, 46 patients were admitted to the critical care department at the Cairo university hospital with acute ST elevation myocardial infarction (STEMI) and amenable to primary coronary intervention were enrolled after being informed about the nature of the study and signing a consent to participate by the responsible family member. 
Methods
Following admission all patients were subjected to the following: Full medical history, clinical examination and laboratory investigations including: Random blood sugar, kidney function tests (BUN, creatinine, Na, and K), liver function tests (PT, PC, SGOT, and SGPT), cardiac enzymes (CK, CK-MB, LDH, and troponin) on admission and 6 and 24 h after intervention and when needed. Hemoglobin, hematocrit and platelets count on admission and 24 h after procedure.
Patients were randomized by alternation (1:1) into two groups before intervention to receive the specific glycoprotein IIb/IIIa inhibitor as follows: 1. Tirofiban group: intravenous high bolus dose 25 lg/kg over 3 min followed by maintenance infusion 0.15 mcg/kg/min. 2. Eptifibatide group: intravenous two boluses 10 min apart (each one is 180 mcg/kg) followed by maintenance 2 mcg / kg /min.
All patients received oral 300 mg aspirin and 600 mg clopidogrel on admission. Other drugs e.g. heparin, statins, nitroglycerin, ACEI, B-blockers, Ca-channel blockers, and antiarrhythmics were given according to standard ESC guidelines management of acute MI. 8 Cardiac catheterization was performed using Judkin's catheter (six French) via right femoral approach in 45 patients (97.8%) and radial approach in one case (2.2%) in the Eptifibatide group as preferred by the angiographer in the absence of peripheral vascular disease. Symptom to balloon time was 7.39 ± 1.6, 7.98 ± 0.95 h in the Tirofiban and Eptifibatide groups, respectively (p = 0.61).Aspiration of thrombus using Diver C device was done in two cases.
Platelet aggregation inhibition assessment: Turbidometric platelet aggregation was done using light transmission aggregometer. Aggregation was performed on CHRONO-LOG platelet aggregometer (Chrono-Log Corporation, 2 W Park Rd., Havertown, PA 19083-4691, USA) using ADP (at concentration, 20M) Blood samples were taken before the start of GP IIb/IIIa inhibitors, 60 min after starting (during) PCI and 6-8 h later, then anticoagulated with citrate and tested for platelet aggregation.
Aggregation % = 100 (baseline platelet count -platelet count after adding ADP)/baseline platelet count. Platelet count drop = the difference between platelet count on admission and the count after 24 h.
Angiographic assessment of TIMI flow and myocardial blush grade (MBG) was done before and at the end of the interventions.
Electrocardiographic assessment: Standard 12-lead ECG ST-segment deviation in all leads is summed and compared before and after intervention. Resolution of ST segment elevation was expressed as a percentage of the initial ST segment elevation.
Bleeding complications: Classified into major and minor bleeding according to the criteria of the Thrombolysis in Myocardial Infarction trials 9 Major bleeding: hemoglobin drop of >5 gm/dl with or without an identified site, intracranial hemorrhage or cardiac tamponade. Minor bleeding: hemoglobin drop of >3 gm/dl with bleeding from a known site, spontaneous gross hematuria, hematemesis, or hemoptysis.
Site access complications: A-V fistula, pseudoaneurysm, major hematoma (hematoma + 15% decrease in hematocrite ratio) or the need for surgical repair.
Major adverse cardiac events (MACE) referred to a composite of endpoints in PCI trials to describe the clinical outcome: death, non-fatal MI, a new myocardial infarction was defined as the finding of levels of the MB isoform of creatine kinase that were at least three times the upper limit of the normal range in two separate blood samples or by the finding of abnormal Q waves in two or more contiguous leads and TVR (target vessel revascularization).
Statistical analysis
Data were collected and coded prior to analysis using the professional statistical Package for Social Science (SPSS 17). All data were expressed as mean and standard deviation (SD). Frequency tables for all categorical data. Student's t-test (unpaired) after checking normality for all continuous data. Mann Whitney test was used when the value of standard deviation was violated. Chi-square test for all categorical data to test for the presence of an association. For small sample size fisher 
Results
Demographic and clinical data
The total patients in our study included 46 patients, 40 males (87%) and six females (13%) with a mean age of 55 ± Baseline clinical characteristics were comparable in both groups regarding age, sex and risk factors for coronary artery disease (hypertension, diabetes mellitus, smoking, dyslipidemia, and a family history of ischemic heart diseases) and site of myocardial infarction but significant previous history of ischemic heart diseases (p 0.033) Table. 1.
Platelet aggregation inhibition
Tirofiban group: The mean platelet aggregation inhibition was 15.5 ± 1.77% on admission, 87.62 ± 3.20% during PCI (60-90 min after bolus), and 78.5 ± 7.07% 6-8 h later.
Eptifibatide group: The mean platelet aggregation inhibition was 15.71 ± 1.38% on admission, 93.57 ± 2.07% during PCI (60-90 min after bolus), 89.85 ± 2.03% 6-8 h later Fig. 1 .
Drug induced thrombocytopenia: There was no significance in platelet count drop (39.04 ± 34.41 versus 46.73 ± 41.48, p 0.37) in Tirofiban versus Eptifibatide groups, respectively. One case of Tirofiban group developed thrombocytopenia (plt count dropped from 207,000 to 44,000cell/cmm within 24 h, which was complicated by cerebral hemorrhage.
TIMI flow (post PCI)
Tirofiban group: TIMI flow post PCI was II in two cases (8.7%) and was III in 21 cases (91.3%).
Eptifibatide group: TIMI flow post PCI was II in one case (4.3%) and was III in 22 cases (95.7%).
There was no statistical significance between both groups (p = 1) Fig. 2. 
Platelet inhibition and TIMI flow
Patients with TIMI flow III had a mean platelet inhibition of 90.2 ± 4.6% while patients with TIMI II flow had mean platelet inhibition of 89 ± 1.4% (p = 0.71). There was no significant statistical correlation between platelet aggregation inhibition and TIMI flow post PCI. Specificity 66.7%, PPV 93.9% and NPV 76.9% (AUC 0.81).
ST segment resolution (STR)
STR was more than 70% in 9(39.13%) versus 15(56.22%) patients of Tirofiban versus Eptifibatide groups respectively (p = 0.005).
Platelet inhibition and STR: Patients with STR >70% had mean platelet aggregation inhibition of 92.92 ± 2.49% while patients with STR <70% had mean platelet inhibition of 87.31 ± 4.15%.
There was a positive statistical correlation between platelet inhibition and STR. the more platelet inhibition at the time of PCI, the better STR (p 0.013, r 0.711).
The cut-off point for platelet aggregation inhibition as a predictor of ST segment resolution >70% was 89.5% with a sensitivity of 92.3% and a specificity of 69.2%, positive predictive value of 75% and a negative predictive value of 10% (AUC 0.87) Fig 3. (AUC0.87, cut-off point 89.5%, sensitivity 92.3%, specificity 69.2%, PPV 75% and NPV 10%, p = 0.013). Table. 2.
Myocardial blush grade (MBG)
Platelet inhibition and MBG: Patients with MBG P2 had a mean platelet aggregation inhibition of 90.6 ± 4.42% while patients with MBG 0-1 had a mean platelet inhibition of 86.3 ± 2.08%.
There was a significant positive statistical correlation between platelet inhibition and MBG (p = 0.045, r = 0.453).
The cut-off point for platelet aggregation inhibition as a predictor of MBG 2-3 was 87.5% with a sensitivity of 73.6% and a specificity of 66.7%, PPV 93.9% and NPV 76.9% (AUC 0.81) Fig. 4 .
Complications
Bleeding complications
Total patients: Nine patients (19.6%) developed minor bleeding while one patient (2.2%) developed major bleeding.
There were no site access complications (A-V fistula, pseudoaneurysm, and major haematoma).
During 30 days follow up, there was one patient (2.2%) with minor bleeding.
Tirofiban group: Five patients (21.7%) had minor bleeding in the form of haematuria, one patient (4.3%) developed major bleeding in the form of cerebral haemorrhge and no site access complications. One patient (4.3%) developed haematuria and was diagnosed to have multiple renal stones. Eptifibatide group: Four patients (17.4%) developed minor bleeding in the form of haematuria and no major bleeding or site access complications. There was no 30 day bleeding.
Catheter related complications
Coronary dissection: One patient (4.3%) of the Tirofiban group developed coronary dissection of LAD proximal to the stent so another stent was deployed with TIMI flow III with no residual stenosis. Coronary dissection did not occur in the Eptifibatide group.
Distal embolization: One patient (4.3%) of Tirofiban group developed distal embolization during PCI to LAD with MBG 0-1 and unsuccessful STR. distal embolization did not occur in the Eptifibatide group.
Coronary perforation: Did not occur in any patient of the Tirofiban or Eptifibatide groups.
Hospital course
Length of stay: The average length of stay was 6.08 ± 2.62 days versus 5.04 ± 1.06 days, p = 0.06 in the Tirofiban versus Eptifibatide groups, respectively.
Echocardiography: It was done within 72 h after PCI in total tested patients. EF was 55.04 ± 8.5% versus 56.5 ± 6.2% (p = 0.49) in Tirofiban versus Eptifibatide groups, respectively. There were no mechanical complications in any patients.
Arrhythmias:
Complete heart block: Postinfarction angina: It occurred in seven patients (30.4%) of the Tirofiban group and only one patient (4.3%) of the Eptifibatide group (p 0.023).
Major adverse cardiac events (MACE)
Post procedural myocardial infarction: It occurred in 4(17.4%) patients of the Tirofiban group and did not occur in the Eptifibatide group (p = 0.12). The culprit vessel was LAD in the four patients, one of them was associated with fatal ventricular tachycardia/ventricular fibrillation (VT/VF) while the other two cases did coronary angiography revealing acute instant thrombosis to which revascularization with stenting was done, the fourth patient developed myocardial infarction after 2 weeks of PCI while doing endoscopic ureteric stone extraction with stoppage of clopidogrel and aspirin due to haematuria.
Target vessel revascularization (TVR): It was done in 2(8.7%) patients of the Tirofiban group and was not needed in the Eptifibatide group (p = 0.24) Table. 3.
Death: In-hospital mortality was 2(8.7%) patients of the Tirofiban group, one of them died from massive cerebral hemorrhage within 24 h of PCI while the other patient died from fatal VT/VF 2 h after PCI to LAD. Three weeks after hospital discharge, death occurred in 1(4.3%) patient versus 1(4.3%) patient (p = 1.00) of the Tirofiban versus Eptifibatide groups, respectively, both cases developed sudden cardiac death at home within 1 h of chest pain. The patient of the Tirofiban group had two vessel disease (LAD and LCX) and primary PCI was done to LCX with unsuccessful STR while the patient of the Eptifibatide group had multivessel disease and primary PCI was done to LAD with successful STR.
Discussion
Our study showed that the mean platelet aggregation inhibition by turbidometric aggregometry was significantly less inhibited by high dose Tirofiban versus Eptifibatide 60 min from the start of PCI (87.62 ± 3.2% versus 93.57 ± 2.07%, p < 0.001) and 6 h after PCI was (78.5 ± 7.07% versus 89.85 ± 2.03%, p < 0.001) while there was not any significant difference on admission (15.5 ± 1.77% versus 15.7 ± 1.38%, p 0.8) in Tirofiban versus Eptifibatide groups, respectively. Batchelor et al. 10 in the COMPARE trial of platelet inhibition also utilizing turbidimetric aggregometry, showed that platelet aggregation at 15 and 30 min was significantly less inhibited by the traditional dose (10 ug) of Tirofiban compared with abciximab (p 0.028) and Eptifibatide regimens (p 0.0001), but there were no significant differences between all GP2b3a regimens after 4.12 and 18 h (p > 0.05). The Eptifibatide regimen inhibited platelet aggregation most consistently throughout both the early and late periods, while the abciximab regimen showed increasingly varied anti-aggregatory effects during continued infusion for >4 h. Danzi et al. 11 used the Ultegra Rapid Platelet Function Assay, showed that platelet inhibition was nonsignificantly different at 10 min (92 ± 6% versus 95 ± 5%, p 0.27) then at 8 h (92 ± 6% versus 89 ± 10%, p 0.62) in the Eptifibatide versus high dose (25 ug) Tirofiban groups, respectively. This difference may be due to different methods of platelet inhibition testing and too early testing after the bolus dose without comparative sequential timed sampling at longer time intervals.
Platelet count drop was non-significant (39.04 ± 34.41 versus 46.73 ± 41.48, p 0.37) in Tirofiban versus Eptifibatide groups, respectively. This is consistent with Dasgupta et al. 12 pooled analysis of eight placebo-controlled, randomized, large trials and concluded that small-molecule GP IIb/IIIa inhibitors (Tirofiban and Eptifibatide) did not significantly increase mild or severe thrombocytopenia compared with placebo and that thrombocytopenia associated with GP IIb/IIIa inhibition does not routinely lead to severe bleeding complications.
We found that post-procedural TIMI grade III was nonsignificantly different (91.3% versus 95.7%, p 1.00) in Tirofiban versus Eptifibatide groups, respectively and TIMI flow II was observed in (8.7% versus 4.3%, p 1.00) in Tirofiban versus Eptifibatide groups, respectively. This finding is consistent with Abuarab et al. 13 randomized trial that compared the intracoronary double bolus of Eptifibtide and high bolus dose of Tirofiban as adjuncts to primary PCI in patients with anterior STEMI and concluded that there was no significant difference in post procedural TIMI III flow in both groups. De Luca et al.
14 meta-analysis of six randomized trials concluded that there was no significant difference in post-procedural TIMI flow grade III (89.8% versus 89.1%, p 0.72) in abciximab versus Eptifibatide and Tirofiban, respectively.
Successful ST segment resolution (STR) more than 70% was found to be significantly lower with high dose Tirofiban that Eptifibatide (39.13% versus 56.22%, p 0.005) in Tirofiban versus Eptifibatide groups, respectively. Patients with successful STR had a mean platelet aggregation inhibition of 92.2 ± 3.5% while patients with unsuccessful STR had a mean platelet inhibition of 85.5 ± 2.2%. This was supported by a significant positive statistical correlation between platelet inhibition and STR (p 0.013, r 0.71).
The cut-off point for platelet aggregation inhibition as a predictor of STR >70% was 89.5% (sensitivity 92.3%, specificity 69.2%, PPV 75% and NPV 10%, AUC 0.87). Abuarab et al. 13 also concluded that in anterior infarction, successful ST segment resolution (70.9 ± 11.3 versus 59.7 ± 9, p < 0.001) in intracoronary Eptifibatide versus Tirofiban, respectively. Marzocchi et al. 16 in the facilitated angioplasty with Tirofiban or Abciximb (FATA) trial failed to show the equivalence of high bolus dose of Tirofiban and abciximab regarding complete STR (67.05% versus 70.45%, p < 0.05) as adjunctive therapy to primary PCI. Zeymer et al. 15 in the EVA-AMI randomized controlled multicenter concluded that Eptifibatide is equally effective as abciximab with respect to STR in patients with STEMI.
The mean myocardial blush grade (MBG) was (2.09 ± 0.73 versus 2.87 ± 0.34, p < 0.001) in the Tirofiban and Eptifibatide groups, respectively. There was a positive correlation between platelet inhibition and MBG (p 0.045, r 0.453).The cut-off point for platelet aggregation inhibition as a predictor of MBG 2-3 was 87.5% (sensitivity 73.6%, specificity 66.7%, PPV 93.9% and NPV 76.9%, AUC 0.81).
Abuarab et al. 13 similarly concluded that MBG II and III indicating successful reperfusion was achieved in 76.6% versus 36.6%, (p 0.005) in intracoronary Eptifibatide versus high dose Tirofiban group, respectively.
In our study, STR and MBG P2 were concordant with each other as markers of myocardial reperfusion. De Luca et al. 18 used STR and MBG (concordant relation) to assess myocardial perfusion in patients with STEMI after primary PCI. Haager et al. 19 evaluated myocardial blush grade 0-1 (p = 0.033) and persistent ST segment elevation (p = 0.017) as independent predictors for long-term mortality after angioplasty in AMI. Sorajja et al. 17 assessed the 30 days and 1 year clinical outcomes of 456 patients using STR >70% and MBG after primary PCI and concluded that both STR and MBG are measures of reperfusion success that strongly correlate with survival and assessment of both yields greater prognostic information than either one alone. Since MBG reflects microvascular patency facilitating myocardial reperfusion while STR reflects cellular integrity and the dynamic and evolving changes after myocardial reperfusion, the two parameters may not necessarily be concordant.
Our monitoring for complications showed that minor bleeding, in the form of haematuria, occurred (21.7% versus 17.4%, p 0.5) in Tirofiban versus Eptifibatide groups, respectively. Major bleeding, in the form of cerebral hemorrhage occured (one patient 4.3% versus 0, p 0.5) in Tirofiban versus Eptifibatide groups, respectively. Thirty days bleeding occurred in (4.3% versus 0, p 0.5) in Tirofiban versus Eptifibatide groups, respectively which was in form of minor bleeding (haematuria) and the patient was diagnosed to have renal stones. There were no site access complications in both groups.
De Luca et al. 24 meta-analysis of six randomized trials comparing abciximab versus small molecules (Eptifibatide and Tir-ofiban) in primary angioplasty concluded that there was no difference in major bleeding complications (1.3% versus 1.9%, p 0.27). Casterella et al. 20 studied 4321 patients undergoing PCI and received a single GP IIb/IIIa inhibitor (abciximab, 1178; Eptifibatide, 1698; Tirofiban, 1445). Major bleeding complications were rare, ranging from 1.9% to 3.1%, and transfusion rates were low, ranging from 0.8% to 2.1%, with no significant differences among the agents evaluated.
We found no significant differences between Tirofiban and Eptifibatide groups regarding procedure related complications (coronary dissection, distal embolization and coronary perforation), length of hospital stay, post procedure echocardiography and arrhythmias. There was significant statistical difference between both groups regarding postinfarction angina (4.3% versus 30.4%, p 0.023) in Eptifibatide versus Tirofiban groups, respectively. Our results were similar to those of Abuarab et al. 13 that showed recurrent ischemia (0% versus 16.7%, p 0.026) in Eptifibatide versus Tirofiban groups, respectively. There was no statistically significant difference between the two groups regarding total MACE. Thirty days mortality was 3(13%) versus 1(4.3%) (p 0.34) of Tirofiban versus Eptifibatide groups, respectively. Post-procedural myocardial infarction occurred in four patients (17.4%) of the Tirofiban group and did not occur in the Eptifibatide group (p 0.12). Target vessel revascularization (TVR) was done in two patients (8.7%) of the Tirofiban group while it was not needed (0%) in the Eptifibatide group (p 0.24). Abuarab et al. 13 concluded that there was no significant difference in the rate of in-hospital MACE among both groups with one death (3.3%) in each group, but recurrent ischemia was higher in the Tirofiban group (0% versus 16.7%, p 0.026) in intracoronary Eptifibatide versus Tirofiban groups, respectively. Casterella et al. 20 showed that there were no significant differences in 1-year mortality, myocardial infarction, and urgent target vessel revascularization was identified among abciximab, Eptifibatide and Tirofiban. Zeymer et al. 15 in EVA-AMI randomized controlled trial showed that mortality was (6.2% versus 4.5%, p 0.5), reinfarction (0.4% versus 3.5%, p 0.03), TVR (4.4% versus 6.5%, p 0.4), stroke (0.5% versus 0.5%, p 1.00) after 6 months of Eptifibatide and abciximab, respectively and concluded that Eptifibatide is equally effective as abciximab in patients with STEMI. Gum et al. 21 evaluated the outcomes of 3541 patients who underwent primary PCI for STEMI and concluded that there was no difference in the incidence of in-hospital death (4.1% versus. 3.5%, p 0.39), recurrent myocardial infarction (0.8% versus. 1.2%, p 0.42), or stroke/transient ischemic attack (0.7% versus. 0.6%, p 0.80) in abciximab versus Eptifibatide patients respectively, so that the study concluded that there was no apparent difference in early outcomes of patients treated with Eptifibatide compared with patients treated with abciximab. Another comparative multicenter study by Akerblom et al. 22 compared all (n = 11.479) STEMI patients, in Sweden who underwent primary PCI and concluded that Eptifibatide is noninferior to abciximab with respect to death or myocardial infarction during one year. Our results together with the other previous studies all support that there are no significant differences regarding the complication rates between different regimens of GP2b3a antagonists used in primary PCI of patients with STEMI.
Limitations of the study
The small sample size of the study. The evidence of myocardial reperfusion could have been supported by myocardial scintigraphic imaging. The absence of long term follow up since the beneficial effects observed in terms of epicardial recanalization and myocardial perfusion may be translated into benefits in terms of left ventricular remodeling and larger survival benefits at long term.
Conclusions
Eptifibatide achieves better platelet aggregation inhibition 60 min after bolus and 6 h after PCI than high dose Tirofiban. Eptifibatide is associated with better myocardial perfusion as indicated by post procedural mean MBG and STR >70% than high dose Tirofiban. Platelet aggregation inhibition during PCI was significantly correlated with STR and MBG. Platelet aggregation inhibition cut-off point as a predictor of STR >70% was 89.5%, and as a predictor of MBG 2-3 was 87.5%. There were no significant differences between Eptifibatide and Tirofiban regarding thrombocytopenia, major or minor bleeding, MACE and 30 days mortality.
